Galmed Pharmaceuticals (GLMD) Change in Account Payables (2013 - 2026)
Galmed Pharmaceuticals (GLMD) posted quarterly Change in Account Payables of -$279000.0 for Q1 2026, up 23.77% year-over-year from -$225417.2 in Q1 2025, and down 572.88% quarter-over-quarter from $59000.0 in Q4 2025.
Galmed Pharmaceuticals (GLMD) Change in Account Payables (2013 - 2026) Analysis & Trends
Galmed Pharmaceuticals' Change in Account Payables history runs 14 years deep, the most recent figure standing at -$279000.0 for Q1 2026.
- In Q1 2026, Change in Account Payables rose 23.77% year-over-year to -$279000.0; the TTM figure through Mar 2026 stood at $79000.0 (down 30.7% YoY), while the FY2025 annual figure was -$8000.0, up 50.0% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$279000.0, down from $59000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $821000.0 in Q3 2024, with the low at -$1.8 million in Q4 2022.
- The 5-year median for Change in Account Payables is -$157000.0 (2022), against an average of -$193823.5.
- The sharpest annual moves came in 2024 and 2025: Change in Account Payables plunged 49700.0% in 2024, then soared 3152.94% in 2025.
- Galmed Pharmaceuticals' Change in Account Payables stood at -$1.8 million in 2022, then jumped by 122.2% to $405000.0 in 2023, then slumped by 188.4% to -$358000.0 in 2024, then soared by 116.48% to $59000.0 in 2025, then sank by 572.88% to -$279000.0 in 2026.
- Business Quant data shows GLMD's Change in Account Payables at -$279000.0 in Q1 2026, $59000.0 in Q4 2025, and -$254000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Galmed Pharmaceuticals | 2.31 Mn | -9.57 Mn | - | -279,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -279,000.00 |
| Mar 31, 2026 | -279,000.00 |
| Dec 31, 2025 | 59,000.00 |
| Dec 31, 2025 | 59,000.00 |
| Sep 30, 2025 | -254,000.00 |
| Sep 30, 2025 | -254,000.00 |
| Jun 30, 2025 | 553,000.00 |
| Jun 30, 2025 | 553,000.00 |
| Mar 31, 2025 | -366,000.00 |
| Mar 31, 2025 | -366,000.00 |
| Dec 31, 2024 | -358,000.00 |
| Dec 31, 2024 | -358,000.00 |
| Sep 30, 2024 | 821,000.00 |
| Sep 30, 2024 | 821,000.00 |
| Jun 30, 2024 | 17,000.00 |
| Jun 30, 2024 | 17,000.00 |
| Mar 31, 2024 | -496,000.00 |
| Mar 31, 2024 | -496,000.00 |
| Dec 31, 2023 | 405,000.00 |
| Dec 31, 2023 | 405,000.00 |